Sangamo Therapeutics Aktie

NeuKaufen Kaufen Verkaufen Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

0,6094 EUR +0,0537 EUR +9,66 %

21:57:24

STU

0,6510 USD -0,0089 USD -1,35 %

nachbörslich22:20:09

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Smartphone

Marktkap.126,53 Mio. EUR

Div. Rendite0,00%

WKN936386

ISINUS8006771062

SymbolSGMO

Werbung

Sangamo Therapeutics Aktien News

Sortieren:Datum Meistgelesen

01.11.23BusinesswireSangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

25.10.23BusinesswireSangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

20.09.23BusinesswireSangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

08.08.23BusinesswireSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

01.08.23BusinesswireSangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast

20.07.23BusinesswireSangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing

17.07.23BusinesswireSangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids

29.06.23BusinesswireSangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease

22.05.23BusinesswireSangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease

16.05.23BusinesswireSangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

02.05.23BusinesswireSangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

26.04.23BusinesswireSangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results

19.04.23BusinesswireSangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast

22.02.23BusinesswireSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

22.02.23BusinesswireSangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease

21.02.23BusinesswireSangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast

03.11.22BusinesswireSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

27.10.22BusinesswireSangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

12.10.22BusinesswireSangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Nine Patients

04.08.22BusinesswireSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

28.07.22BusinesswireSangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast

21.07.22BusinesswireEuropean Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation

01.06.22BusinesswireSangamo Therapeutics Announces Participation at Upcoming Investor Conferences

05.05.22BusinesswireSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

02.05.22BusinesswireSangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

28.04.22BusinesswireSangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast

21.04.22BusinesswireSangamo Therapeutics Announces Participation at Upcoming Investor Conferences

04.04.22PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Werbung

Sangamo Therapeutics News

Sangamo Therapeutics News: auf dieser Seite finden Sie alle Sangamo Therapeutics News und Nachrichten zur Sangamo Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sangamo Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sangamo Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.